Jul 17, 2024
Propanc Biopharma’s CSO Predicts PRP Could Solve Problem That Impacts Response Rate of Immune Checkpoint Inhibitors Treating Solid TumorsBritish Journal of Cancer Concludes Tumor cell-intrinsic PD-L1 function promotes EMT MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a…
View All Press Releases